Kevin Tan - 09 Jan 2025 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: CFO & Treasurer
Signature: /s/ David Tyronne Howton as attorney-in-fact for Kevin Tan
Issuer symbol: SLDB
Transactions as of: 09 Jan 2025
Net transactions value: -$15,849
Form type: 4
Filing time: 13 Jan 2025, 18:51:18 UTC
Previous filing: 16 Feb 2024
Next filing: 11 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Options Exercise		+11,250	+64%		28,862	09 Jan 2025	Direct	F1, F2
transaction	SLDB	Common Stock	Sale	$15,849	-4,073	-14%	$3.89	24,789	10 Jan 2025	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Restricted Stock Units	Options Exercise	$0	-11,250	-33%	$0.000000	22,500	09 Jan 2025	Common Stock	11,250		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert to common stock on a one-for-one basis.
F2	Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024 and November 29, 2024, respectively.
F3	This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Mr. Tan.
F4	The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.